SNSE
Sensei Biotherapeutics, Inc.Company with tickers: SNSE
CIK
1829802
CUSIP
81728A207
Shares Outstanding
1,341,941
13F Activity (30d)
30 filings
28 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $170,627,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Research & Development | — | ||||
| Operating Income | $-170,627,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Net Income | $-170,236,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Basic) | $-131.45 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Diluted) | $-131.45 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |